- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Gilead's Idelalisib Receives CHMP Recommendation for Treating CLL and FL
The recommendation to the EMA came soon after Zydiga (idelalisib) was approved in the US.
-
Close on the heels of the oncology drug Zydelig (idelalisib 150 mg) gaining approval in the U.S., Gilead Sciences (GILD Analyst Report) announced that the drug has been recommended for approval in the EU by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).
The CHMP has recommended the approval of the drug for treating adults suffering from chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). The favorable opinion from the CHMP will now be reviewed by the European Commission with a final decision expected in the next couple of months.
-
In particular, the CHMP is in favor of the EU approval of Zydelig in combination with Roche/ Biogen Idec’s (RHHBY Analyst Report)/ Rituxan for treating CLL patients who have received at least one prior therapy or as a first-line treatment in CLL patients unsuitable for chemotherapy due to a genetic mutation. The CHMP has also recommended approving the drug as a monotherapy for treating FL patients who have not responded to two prior therapies.
Read the original report here: http://bit.ly/1qh7gmk
Source: Zacks
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Physician-Pharmacy Integration in Cancer Care: Pillars of Medically Integrated Pharmacy
December 16th 2025The foundation of medically integrated pharmacy includes 7 critical pillars. This commentary focuses on the benefits of 3 of those pillars: abandonment, adherence, and access/affordability.
Read More
